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Abstract
Purpose To compare the use of antidepressant (AD) classes
and compounds in individuals who committed suicide and in
controls from the general population and to assess to what
extent adherence and current use of different AD classes can
affect the risk of committing suicide.
Methods Individual data on suicide, diagnoses and AD use in
Friuli Venezia Giulia from 2005 to 2014 were obtained from the
Regional Social and Health Information System. All suicides
that had at least one prescription of AD in the 730 days before
death (N = 876) were included as cases. Each case was matched
with regard to age and sex with five controls from the general
population. The association between suicide and AD use was
assessed using conditional logistic regression analysis.
Results Almost 70% of all suicides occurring in the10-year
period had been prescribed AD. Selective serotonin reuptake
inhibitors (SSRIs) accounted for more than the 90% of
the prescriptions, with paroxetine the most prescribed
AD. All AD compounds and classes were not associated
with a higher suicide risk, with the exception of SSRI
(OR = 1.6). A decreasing trend in suicide risk was
observed when adherent subjects or current AD users
were compared to the others.
Conclusions AD treatment is an important factor for
preventing suicide, since the use of AD at adequate dosage
and for a proper duration was associated with a lower suicide
risk. The proper use of AD should be ascertained by physi-
cians, particularly in a primary care context.
Keywords Suicide . Antidepressants . Adherence . Current
use . Case-control
Electronic supplementary material The online version of this article
(doi:10.1007/s00228-017-2236-0) contains supplementary material,













1 Department of Clinical Neuroscience, Division of Psychiatry,
Karolinska Institutet, Stockholm, Sweden
2 Italian Collaborating Centre for the WHO Family of International
Classifications, Udine, Italy
3 Primary care services Area, Central Health Directorate, Region Friuli
Venezia Giulia, Trieste, Italy
4 Epidemiological Service, Central Health Directorate, Friuli Venezia
Giulia Region, Udine, Italy
5 Department of Medical Sciences, University of Trieste, Trieste, Italy
6 Psychiatric Unit, Department of Experimental and Clinical Medical
Sciences, University of Udine, Udine, Italy
Eur J Clin Pharmacol
DOI 10.1007/s00228-017-2236-0
Introduction
Suicide is a major public health problem. There is a close link
between suicide and psychiatric diseases, foremost depression
[1]. Depression has repeatedly been found to be untreated in
affected individuals [2, 3]. Several studies have documented a
low adherence to antidepressant medication in the general
population, both at the international [4–7] and at the Italian
level [8, 9]. Early discontinuation of antidepressants among
diagnosed patients has also been reported [6, 10–14].
Modifications, such as switching or combining different anti-
depressants, have been shown to seldom occur [9, 11, 14, 15].
In many countries, however, increased use of antidepressants
during the last two decades has been accompanied by de-
creased suicide rates [16, 17]. Such an association has been
documented also in the Italian region of Friuli Venezia Giulia
(FVG) [3]. Furthermore, there is evidence from a Swedish
individual-based study that the association may be the expres-
sion of a causal relationship, and that antidepressants actually
prevent suicide [2]. A British study found that the risk of
suicide among patients treated with antidepressants decreased
with the length of treatment [13]. We had similar findings in
FVG [18]. Furthermore, our study found that the risk of sui-
cide in patients with somatic disorders was not higher than the
risk of the general population, when patients were adherent to
antidepressant medication [19]. Current use of antidepressants
was also associated with a lower risk of suicide deaths [20,
21]. Nonetheless, there is a need for more studies of the effects
of antidepressants on suicide risk, particularly with a focus on
qualitative parameters.
The aims of the present case-control study are the follow-
ing: (i) to compare the pattern of use of different antidepres-
sant classes and compounds in individuals who committed
suicide and in controls from the general population; and (ii)
to assess to what extent adherence and current use of different
antidepressant classes can affect the risk of committing
suicide.
Material and methods
Study design, subjects and diagnoses
Cases and controls were selected from the Regional Social and
Health Information System (SISSR) of the Friuli Venezia
Giulia (FVG) Region, Italy. The system provides a unique
anonymous key, which allows for the linking of data from
different regional databases (the Death Register, the Hospital
Discharge Register and the Drug Prescription Register) [19].
Subjects who committed suicide during a 10-year period
(from 1 January 2005 to 31 December 2014) were identified
through the Death Register, using ICD-9 codes E95* and
E98* for intentional self-harm and events of undetermined
intent. Suicides were then defined as cases provided that they
also had received at least one prescription of an antidepressant
during their last 2 years (730 days) of life. For each case, five
controls were selected from the FVG general population by
using an incidence density sampling method [22]. Controls
were matched by gender and year of birth, had to be alive at
the time of suicide of their corresponding case (index date)
and had to have received at least one prescription of an anti-
depressant in the 730 days prior to the index date.
In the event that suicides and controls had been hospitalised
during the 2 years prior to the index date, the main in-patient
diagnoses were obtained from the Hospital Discharge
Register. Diagnoses were recorded as ICD-9 codes in the first
position on the medical record on discharge from public and
private hospitals covered by the Regional Health System. As
in our previous study [19], they were arranged into three
groups: affective disorders (codes 296, 300.4, 311); non-
affective psychiatric disorders (codes 290–295, 297–300.3,
300.5–310, 312–319); and somatic disorders (codes 001–
289, 320–629, 680–759, 780–799). Complications from preg-
nancy, childbirth and puerperium (codes 630–679); certain
conditions originating in the perinatal period (codes 760–
779); injury and poisoning (codes 800–999) and external
causes of injury and supplemental classification (codes E
and V) are not considered and excluded from the data analy-
ses. The time range for all the diagnostic variables is the
730 days prior to the index date.
Antidepressant prescriptions
Antidepressant data includes all prescriptions filled in FVG in
the 730 days prior to the index date, if prescribed by a general
practitioner (GP) or other public physician. Such prescriptions
are reimbursed by the National Health System and cover more
than 90% of all antidepressant prescriptions in the region [3].
The retrieved data included the prescription date, the number
of packages, the volume (expressed in defined daily doses,
DDD), the specific antidepressant drug name and its ATC
code [23].
The different antidepressant drugs were merged into four
classes: tricyclics TCA (ATC code N06AA), selective seroto-
nin reuptake inhibitors (SSRI) (N06AB), serotonergic norad-
renergic reuptake inhibitors (SNRIs) (N06AX21, N06AX16)
and Bother^ antidepressants (N06AX49, N06AX12,
N06AX11, N06AF03, N06AX03, N06AX18, N06AX05).
The tetracyclic maprotiline (ATC code N06AA2) was includ-
ed in the TCA category.
The total number of prescriptions of each specific antide-
pressant as well as the number of each class was analysed.
Additionally, it determined whether a subject adhered to
antidepressants or was currently using antidepressants at the
time of the index date.
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Adherence to antidepressants was assessed using the med-
ication possession ratio (MPR), which is defined as the pro-
portion of days supplied under a specified time period [24].
The total number of DDD approximated the number of days
of treatment:
MPR ¼ Total number of DDD in the 730 days prior to the index date
730 days
 100
MPR was divided into two groups (1–79; ≥80%). Only
individuals with an MPR ≥ 80% were defined as adherent to
treatment. Adherent individuals were covered by antidepres-
sants for at least 584 days during the 730 days prior to the
index date.
Current use of antidepressants at the time of the index date
was determined by two conditions. First, the total number of
DDD supplied at the second-to-last prescription was sufficient
to cover the time up to the last prescription. Second, the total
number of DDD supplied at the last prescription was sufficient
to cover the time up to the index date.
Furthermore, we assessed the treatment modifications
using two parameters:
1. The number of switches of antidepressant treatments. A
switch is defined as the discontinuation of an index anti-
depressant and the prescription of another specific antide-
pressant. A delay up to 31 days until the prescription of
the new antidepressant as well as an overlap of the two
drugs up to 31 days will be allowed [11].
2. The number of combinations of antidepressant treatments.
Combination is defined as the prescription of the index
antidepressant overlapping the prescription of a second
antidepressant for more than 31 days [11].
The numbers of switches and combinations were calculat-
ed with regard to all the antidepressant compounds, as well as
to the four classes of antidepressants (i.e. TCA, SSRI, SNRI,
other).
Statistical analyses
Continuous variables were summarised using the median as a
measure of central tendency and the range as a measure of
dispersion, whereas dichotomous or categorical variables are
tabulated into contingency tables. For categorical variables,
the chi-square statistic (χ2) was used to test the differences
between observed and expected frequencies.
Conditional logistic regression analysis was used to assess
the associations between outcome (suicide) and predictors
(use of antidepressant).
Crude and adjusted odds ratios (OR) and 95% confidence
intervals (95% C.I.) were estimated from the logistic regres-
sion coefficients and their respective standard errors. A P val-
ue (P) < 0.05 is set as the threshold for statistical significance.
Two conditional logistic regression models were used to as-
sess the crude and adjusted suicide risk in suicides and con-
trols with regard to different antidepressant classes (Model 1)
and compounds (Model 2). Stratified analyses were per-
formed according to adherence and current use of antidepres-
sants. Subjects who were not prescribed the index antidepres-
sant (i.e. SSRI, SNRI, TCA or other) were used as reference
for the conditional regression analyses (OR = 1.0).
Descriptive and inferential analyses were conducted using
the statistical software Stata/SE (version 13.1).
Results
The total number of suicides in FVG during the years 2005–
2014 was 1260. Suicides treated with antidepressants in the
2 years prior to death were 876. The proportion of suicides
treated with antidepressants was greater in females (N = 268;
81%) than that in males (N = 608; 65%) and that in subjects
older than 60 years of age (N = 464; 88%) than that in younger
(N = 412; 56%).
The suicide rate in FVG was 9.4 per 100.000 inhabitants in
2005 and 11.6 per 100.000 inhabitants in 2014. The percent-
age of suicides treated with antidepressants was 69.5% during
the 10-year period.
Diagnoses and antidepressant prescriptions
Diagnoses registered in cases and controls are summarised in
Table 1.
The mean number of prescriptions filled in the 730 days
before the index day was 14.2 in cases (median = 9.5;
range = 1–138) and 10.5 in controls (median = 6; range = 1–
98). SSRI accounted for more than the 90% of the prescrip-
tions in cases, as well as in controls.
Adherence and current use of antidepressants
Three-hundred thirty-four (38%) cases and 1207 (27%) con-
trols had an MPR ≥ 80%, whilst a current use of antidepres-
sants at the time of the index date was found in 392 cases
(45%) and 1382 controls (31%).
Only 235 cases (26.8%) and 797 controls (18.2%) both
adhere and currently use antidepressants at the time of the
index date.
Treatment modifications
The number of cases who switched or combined any
antidepressant compound at least once during the
730 days prior to the index date was, respectively,
414 (47%) and 523 (60%), whilst controls were re-
spectively 1777 (41%) and 1971 (45%). The number
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of switches and combinations with regard to antide-
pressants classes is summarised in Table 1.
Around 20% of cases and controls switched SNRI,
TCA and other antidepressants during the study peri-
od, whilst 17% of cases and 13% of controls switched
SSRI. More than 60% of the cases combined TCA
and other antidepressants with other classes, whilst
controls were around 50%. Forty-three percent cases
and 32% of controls combined SSRI with other
classes.
Table 1 Numbers (N),
percentages (%), crude and
adjusted odds ratio (OR) and 95%
confidence intervals (95% C.I.) of
suicide in antidepressant users in
the 730 days prior to index date.
Data are provided according to
antidepressant classes (Model 1)
and specific antidepressants
(Model 2). Statistically significant






Crude suicide risk Adjusted suicide
riske,f
N % N % OR 95% C.I. OR 95% C.I.
Model 1
Affective disordersa 53 6.0 13 0.3 23.6 12.3–45.2 10.5 5.2–21.2
Non-affective disordersa 107 12.2 62 1.4 9.4 6.8–13.0 7.0 4.9–10.0
Somatic disordersa 389 44.4 2321 53.0 0.7 0.6–0.8 0.6 0.5–0.7
Switches 139 15.9 537 12.2 1.4 1.1–1.7 1.1 0.9–1.4
Combinations 359 41.0 1283 29.3 1.8 1.5–2.1 1.4 1.1–1.7
SSRI 827b 94.4 3987b 91.0 1.7 1.2–2.3 1.6 1.1–2.2
SNRI 610b 69.6 2788b 63.6 1.3 1.1–1.6 1.1 0.9–1.4
TCA 451b 51.5 2005b 45.8 1.3 1.1–1.5 1.0 0.9–1.3
Other 452b 51.6 1912b 43.6 1.4 1.2–1.6 1.1 0.9–1.3
Model 2
Switches 414 47.3 1777 40.6 1.4 1.2–1.6 0.9 0.7–1.2
Combinations 523 59.7 1971 45.0 2.0 1.7–2.3 1.7 1.4–2.2
Paroxetine 623 71.1 2918 66.6 1.2 1.1–1.5 1.0 0.8–1.2
Sertraline 535 61.1 2415 55.4 1.3 1.1–1.5 1.0 0.8–1.2
Citalopram 534 61.0 2355 53.8 1.4 1.2–1.6 1.1 0.9–1.3
Escitalopram 501 57.2 2151 49.1 1.4 1.2–1.7 1.1 0.9–1.4
Fluoxetine 298 34.0 1364 31.1 1.1 1.0–1.3 0.9 0.8–1.1
Fluvoxamine 131 14.9 586 13.4 1.1 0.9–1.4 0.9 0.7–1.1
Venlafaxine 520 59.4 2418 55.2 1.2 1.0–1.4 1.0 0.8–1.2
Duloxetine 354 40.4 1496 34.2 1.3 1.1–1.6 1.1 0.9–1.3
Amitriptiline 328 37.4 1239 32.8 1.2 1.1–1.4 1.0 0.9–1.2
Clomipramine 238 27.2 1084 24.7 1.1 1.0–1.3 0.9 0.7–1.1
Nortriptiline 34 3.9 134 3.1 1.3 0.9–1.9 1.0 0.6–1.6
BOther TCA^c 51 5.8 189 4.3 1.4 1.0–1.9 1.0 0.7–1.5
Trazodone 300 34.2 1277 29.2 1.3 1.1–1.5 1.0 0.9–1.3
Mirtazapine 207 23.6 754 17.2 1.5 1.3–1.8 1.2 1.0–1.4
Reboxetine 67 7.6 294 6.7 1.1 0.9–1.5 1.0 0.7–1.3
Bupropion 60 6.8 232 5.3 1.3 1.0–1.8 1.0 0.7–1.3
Mianserin 47 5.4 202 4.6 1.2 0.8–1.6 1.0 0.7–1.4
BOther^d 4 0.5 6 0.1 3.3 0.9–11.8 3.7 1.0–13.7
AD antidepressants, SSRI selective serotonin reuptake inhibitor, SNRI serotonergic noradrenergic reuptake inhib-
itor, TCA tricyclics, Other Bother^ antidepressants
a Crude and adjusted ORs are shown only in Model 1
b The sum is lower than the sum of patients within each specific antidepressant, due to switches and combinations
c Trimipramine, imipramine,desipramine, dosulepine, maprotiline
d Ademetionin, phenelzine
e Adjusted for AD classes, switches to other AD classes, combinations with other AD classes, affective psychiatric
disorders, non-affective psychiatric disorders and somatic disorders (Model 1)
f Adjusted for switches to other AD, combinations with other AD, affective psychiatric disorders, non-affective
psychiatric disorders and somatic disorders (Model 2)
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Antidepressants monotherapy
When only subjects who had neither switched nor combined
antidepressant classes were considered, 51 cases out of 491
(10%) and 204 controls out of 2895 (7%) had an MPR ≥ 80%
in the 730 days prior to the index date. SSRI had the lowest
proportion with regard to MPR ≥ 80% in both cases and con-
trols (8 to 11.5%), whilst TCA and other antidepressants had
the highest proportion (16.2 to 19%) (Online Resource 1).
When the current use of antidepressants at the time of the
index date was assessed, cases using only one antidepressant
class were 134 (27%) and controls were 512 (18%).
Conditional regression analyses
As summarised in Table 1, in the crude analysis, the risk of
suicide was increased in all antidepressant classes (Model 1),
as well as in 10 out of 18 antidepressant compounds (Model
2). After adjusting for treatment modifications and for psychi-
atric and somatic diagnoses, the risk of suicide increased sig-
nificantly only in SSRI (OR = 1.6), as well as in combinations
and in affective and other psychiatric diagnoses (Model 1). In
all different antidepressant compounds, the adjusted risk was
not significant (Model 2).
In the stratified analyses, the risk of suicide decreased in all
classes, when comparing subjects with an MPR ≥ 80% to
subjects with an MPR 1–79%, but it was significant only in
SSRI (OR = 1.6, 95% C.I. = 1.1–2.3) and in SNRI (OR = 1.2,
95% C.I. =1.0–1.5) with an MPR 1–79% (Fig. 1). The risk
could not be assessed in subjects adherent to SSRI, since all
cases and controls adherent to antidepressants (MPR ≥ 80%)
had at least one prescription of SSRI.
A decreasing risk was found in SSRI users, when stratified
analyses compared subjects that were currently using antide-
pressants at the time of the index date to those that were not. A
higher risk of suicide was significant in subjects who did not
currently use SSRI (OR = 1.4, 95% C.I. = 1.0–1.9), whilst
current TCA users showed a lower risk (OR = 0.7, 95%
C.I. = 0.5–1.0) (Fig. 2).
Discussion
This study could not assess significant associations between
antidepressants and suicide risks, with regard to different an-
tidepressant classes, but SSRI, and all antidepressant com-
pounds. The finding of a higher suicide risk in SSRI was in
contrast with a previous case-control study, which did not
observe such higher risk [25]. A post-mortem toxicological
screening also demonstrated a lower suicide risk in SSRI users
[26].
However, we found a decreasing trend in suicide risk when
subjects who adhered to antidepressants were compared to
subjects who did not adhere. Similar findings were observed
when current use of antidepressants was assessed. Although
we did not find previous studies assessing the difference in
suicide risk with regard to adherence in the general popula-
tion, Danish studies observed that the risk of suicide decreased
along with a continued treatment with antidepressants,
assessed by the number of prescriptions [27, 28]. Current
use of antidepressants had been further found to be associated
to a lower suicidal risk in studies at the population level, with
SSRI associated to the lowest suicide risk [20, 21].
In our study, SSRI was the antidepressant class more fre-
quently prescribed, consistent with other Italian and interna-
tional studies [3, 8, 10, 12, 29], with paroxetine the most
prescribed SSRI [10]. We demonstrated, however, that only
one in ten subjects prescribed SSRI alone adhered to treat-
ment. A low adherence to antidepressants had been found in
several studies among depressed patients [6–11, 14]. Our find-
ing of an adherence rate twice as high in TCA users compared
to that of SSRI users, nonetheless, might reflect a greater ef-
ficiency of TCA in treatment-resistant depression [27], as well
as the fact that patients may be more experienced in using
older medications for their illness [7]. This might also explain
our finding of a lower suicide risk in subjects currently using
TCAs. On the other hand, the higher adherence found in
Bother antidepressants^ such as trazodone and mirtazapine is
not easily explainable. It may be confounded by indication,
since these antidepressants are widely used in sleeping disor-
ders, with positive outcomes [30].
The high rate of treatment modifications that we observed
in suicide victims, as well as the higher suicide risk in subjects
who combined antidepressants, is also of interest. Although
the indication for switching or combining antidepressants
regards the patients with treatment-resistant depression [31],
previous studies have suggested that patients who receive
more prescriptions [32], as well as frequently change treat-
ment [11, 15, 33], may be more resistant to antidepressants.
This can be associated with severe depressive symptoms and a
consequent greater suicidal risk [27]. Among the antidepres-
sant classes, SSRIs were less likely to be subjected to treat-
ment modifications, as observed in other research [11, 34].
This may be related to their better tolerability [11]. On the
other hand, TCA and Bother^ antidepressants were combined
with other classes twice as often as SSRI, indicating such
classes being more used for combination strategies [35].
It should be taken in account that in Italy, the major-
ity of antidepressant prescribers are GPs, who might
prefer to prescribe SSRIs, due to their milder side-
effect profile. Previous studies, however, observed that
GPs may be less able to monitor treatment and to assess
and manage suicide risk when compared to psychiatrists
[10, 11, 14]. GPs might also be more likely to either
stop previous treatment or to modify the treatment fre-
quently in case of resistant depression.
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Strengths and limitations
The strength of this study is that it is a population-based study
of all suicides treated with antidepressants occurring during a
10-year period with matched controls. It is adjusted for several
confounding factors, such as in-patient diagnoses and treat-
ment modifications. The study design avoids information and
selection bias, since it is based on administrative data with full
coverage of the regional population [19].
Some limitations should be taken into account. Only anti-
depressant prescriptions issued by GPs and other public phy-
sicians were available from the health database. These, how-
ever, constitute 90% of the prescriptions [3].
As in other studies based on prescription registers [7, 11,
14, 18, 19, 27, 36], patients’ actual adherence and compliance
to treatment could not be assessed.We used the DDD to assess
the MPR, however, one DDD only approximates the average
recommended dose per day [36]. Therefore, a possible over-
estimation of the drug compliance should be taken into
account.
Stratified analyses were in some instances hindered by the
fact that suicide is a rare event that the available suicide data in
this region over 10 years provides limited statistical power.
Interesting but not possible analyses were, for example, in
subjects with specific age groups or genders or in subjects
who used only one class of antidepressant during the study
Fig. 1 Adjusted odds ratio (OR) and 95% confidence intervals (95%
C.I.) of suicide in antidepressant (AD) users according to the adherence
to antidepressants in the 730 days prior to index date. The medical
possession ratio (MPR) was used to assess adherence to treatment. Data
are provided according to AD classes. Stratified analysis was performed
comparing subjects who were not adherent to treatment (MPR 1–79%)
with subjects adherent to treatment (MPR ≥ 80%). ORs were adjusted for
AD classes, switches to other AD classes, combinations with other AD
classes, affective psychiatric disorders, non-affective psychiatric
disorders and somatic disorders
Fig. 2 Adjusted odds ratio (OR) and 95% confidence intervals (95%
C.I.) of suicide in antidepressant (AD) users according to the current
use of antidepressants sufficient to cover the time of the index date.
Data are provided according to AD classes. Stratified analysis was
performed comparing subjects who were not current users of AD with
subjects who were current users. ORs were adjusted for AD classes,
switches to other AD classes, combinations with other AD classes,
affective psychiatric disorders, non-affective psychiatric disorders and
somatic disorders
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period, the directions of switch or the types of combinations
within different antidepressant classes. The database did not
provide information on the reasons for treatment changes.
Analyses of diagnoses were only possible for those sub-
jects who had received in-patient care, who probably were
more severely ill [19]. The fact that outpatient diagnoses were
not available may have led to an underestimate of affective
disorders as an indication for antidepressant. This, however,
seems a minor issue, since previous database analyses showed
that antidepressants are prescribed for depression in more than
half of the cases [37]. Furthermore, a previous study indicated
that the ability of Italian GPs to detect moderate to severe
depression is satisfactory [29].
Other limitations regarded the inability of adjusting the
analyses for other factors, such as socio-economic variables,
as well as the lack of information on suicide methods, above
all antidepressant poisoning [19].
Conclusions
Notwithstanding the limitations, our observations support the
hypothesis that antidepressant treatment is an important factor
for preventing suicide. This is supported by the fact that long
adherence and current use of antidepressants at the time of
death were associated with a lower suicide risk. Since primary
care physicians are the most common prescribers of antide-
pressants, they should ascertain that antidepressants are prop-
erly used.
Further research is needed to more closely examine the
links between antidepressant use and suicide risk.
Acknowledgments The authors thank Loris Zanier at Epidemiological
Service, Central Health Directorate, Friuli Venezia Giulia Region, Italy,
and Paola Ducolin at Video-Stitch, France, for help in retrieving and
processing data on suicides and controls. The authors also thank
Mrs.Jennifer Coppola for the linguistic review.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Isometsa E (2014) Suicidal behaviour in mood disorders—who,
when, and why? Can J Psychiatr 59(3):120–130
2. Isacsson G, Holmgren A, Osby U, Ahlner J (2009) Decrease in
suicide among the individuals treated with antidepressants: a con-
trolled study of antidepressants in suicide, Sweden 1995–2005.
Acta Psychiatr Scand 120(1):37–44
3. Castelpietra G,MorsanuttoA, Pascolo-Fabrici E, IsacssonG (2008)
Antidepressant use and suicide prevention: a prescription database
study in the region Friuli Venezia Giulia, Italy. Acta Psychiatr
Scand 118(5):382–388
4. Olfson M, Marcus SC, Tedeschi M, Wan GJ (2006) Continuity of
antidepressant treatment for adults with depression in the United
States. Am J Psychiat 163(1):101–108. doi:10.1176/appi.ajp.163.1.
101
5. Krivoy A, Balicer RD, Feldman B, Hoshen M, Zalsman G,
Weizman A, Shoval G (2015) The impact of age and gender on
adherence to antidepressants: a 4-year population-based cohort
study. Psychopharmacology 232(18):3385–3390. doi:10.1007/
s00213-015-3988-9
6. Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T,
Kashima H (2009) Persistence and compliance to antidepressant
treatment in patients with depression: a chart review. BMC
Psychiatry 9:10. doi:10.1186/1471-244x-9-38
7. Serna MC, Cruz I, Real J, Gasco E, Galvan L (2010) Duration and
adherence of antidepressant treatment (2003 to 2007) based on
prescription database. Eur Psychiatry 25(4):206–213
8. Poluzzi E, Piccinni C, Sangiorgi E, Clo M, Tarricone I, Menchetti
M, De Ponti F (2013) Trend in SSRI-SNRI antidepressants pre-
scription over a 6-year period and predictors of poor adherence.
Eur J Clin Pharmacol 69(12):2095–2101. doi:10.1007/s00228-
013-1567-8
9. Degli Esposti L, Piccinni C, Sangiorgi D, Fagiolini A, Buda S
(2015) Patterns of antidepressant use in Italy: therapy duration,
adherence and switching. Clinical Drug Investigation 35(11):735–
742. doi:10.1007/s40261-015-0332-4
10. Trifiro G, Tillati S, Spina E, Ferrajolo C, Alacqua M, Aguglia E,
Rizzi L, Caputi AP, Cricelli C, Samani F (2013) A nationwide
prospective study on prescribing pattern of antidepressant drugs in
Italian primary care. Eur J Clin Pharmacol 69(2):227–236
11. Milea D, Guelfucci F, Bent-Ennakhil N, ToumiM, Auray JP (2010)
Antidepressant monotherapy: a claims database analysis of treat-
ment changes and treatment duration. Clin Ther 32(12):2057–
2072. doi:10.1016/j.clinthera.2010.11.011
12. Wu CS, Shau WY, Chan HY, Lee YC, Lai YJ, Lai MS (2012)
Utilization of antidepressants in Taiwan: a nationwide population-
based survey from 2000 to 2009. Pharmacoepidemiol Drug Saf
21(9):980–988. doi:10.1002/pds.3255
13. Jick H, Kaye JA, Jick SS (2004) Antidepressants and the risk of
suicidal behaviors. JAMA 292(3):338–343
14. Wu CS, Shau WY, Chan HY, Lai MS (2013) Persistence of antide-
pressant treatment for depressive disorder in Taiwan. Gen Hosp
Psychiatry 35(3):279–285
15. Marcus SC, Hassan M, Olfson M (2009) Antidepressant switching
among adherent patients treated for depression. Psychiatr Serv
60(5):617–623
16. Isacsson G (2000) Suicide prevention—a medical breakthrough?
Acta Psychiatr Scand 102(2):113–117
17. GusmaoR, Quintao S, McDaid D, Arensman E, VanAudenhove C,
Coffey C, Varnik A, Varnik P, Coyne J, Hegerl U (2013)
Antidepressant utilization and suicide in Europe: an ecological
multi-national study. PLoS One 8(6):15. doi:10.1371/journal.
pone.0066455
18. Castelpietra G, Bovenzi M, Clagnan E, Barbone F, Balestrieri M,
Isacsson G (2016) Diagnoses and prescriptions of antidepressants
in suicides: register findings from the Friuli Venezia Giulia Region,
Italy, 2002–2008. International Journal of Psychiatry in Clinical
Practice:1–4. doi: 10.3109/13651501.2016.1149196
Eur J Clin Pharmacol
19. Castelpietra G, Gobbato M, Valent F, Bovenzi M, Barbone F,
Clagnan E, Pascolo-Fabrici E, Balestrieri M, Isacsson G (2015)
Somatic disorders and antidepressant use in suicides: a
population-based study from the Friuli Venezia Giulia region,
Italy, 2003-2013. J Psychosom Res 79(5):372–377. doi:10.1016/j.
jpsychores.2015.09.007
20. Haukka J, Arffman M, Partonen T, Sihvo S, Elovainio M, Tiihonen
J, Lonnqvist J, Keskimaki I (2009) Antidepressant use and mortal-
ity in Finland: a register-linkage study from a nationwide cohort.
Eur J Clin Pharmacol 65(7):715–720. doi:10.1007/s00228-009-
0616-9
21. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Tanskanen A,
Haukka J (2006) Antidepressants and the risk of suicide, attempted
suicide, and overall mortality in a nationwide cohort. Arch Gen
Psychiatry 63(12):1358–1367. doi:10.1001/archpsyc.63.12.1358
22. Satchi T, Mounib EL (2000) Automating the Selection of Controls
in Case-Control Studies. SAS Users Group International, SUGI:
SAS Users Group International Annual conference; 25th
23. WHO Collaborating Centre for Drug Statistics Methodology
(2015) Guidelines for ATC classification and DDD assignment
2015. Oslo
24. Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for
evaluation of medication adherence and persistence using automat-
ed databases. Pharmacoepidemiol Drug Saf 15(8):565–574. doi:10.
1002/pds.1230
25. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J,
Evans S, Gunnell D (2005) Antidepressant treatment and the risk of
fatal and non-fatal self harm in first episode depression: nested case-
control study. BMJ 330(7488):389
26. Isacsson G, Holmgren P, Ahlner J (2005) Selective serotonin reup-
take inhibitor antidepressants and the risk of suicide: a controlled
forensic database study of 14,857 suicides. Acta Psychiatr Scand
111(4):286–290
27. Sondergard L, Kvist K, Andersen PK, Kessing LV (2006) Do anti-
depressants prevent suicide? Int Clin Psychopharmacol 21(4):211–
218
28. Sondergard L, Lopez A, Andersen PK, Kessing LV (2007)
Continued antidepressant treatment and suicide in patients with
depressive disorder. Arch Suicide Res 11(2):163–175. doi:10.
1080/13811110701249889
29. Balestrieri M, Carta MG, Leonetti S, Sebastiani G, Starace F,
Bellantuono C (2004) Recognition of depression and appropriate-
ness of antidepressant treatment in Italian primary care. Soc
Psychiatry Psychiatr Epidemiol 39(3):171–176
30. Savarese M, Carnicelli M, Cardinali V, Mogavero MP, Federico F
(2015) Subjective hypnotic efficacy of trazodone and mirtazapine
in patients with chronic insomnia: a retrospective, comparative
study. Archives italiennes de biologie 153 (2–3):243–250. doi:10.
12871/0003982920152348
31. Nemeroff CB (2007) Prevalence and management of treatment-
resistant depression. J Clin Psychiatry 68:17–25
32. CrownWH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ,
Russell JM (2002) The impact of treatment-resistant depression on
health care utilization and costs. J Clin Psychiatry 63(11):963–971
33. Cheung K, Aarts N, Noordam R, van Blijderveen JC, Sturkenboom
MC, Ruiter R, Visser LE, Stricker BH (2015) Antidepressant use
and the risk of suicide: a population-based cohort study. J Affect
Disord 174:479–484. doi:10.1016/j.jad.2014.12.032
34. Simon GE, Heiligenstein J, Revicki D, VonKorff M, Katon WJ,
Ludman E, Grothaus L, Wagner E (1999) Long-term outcomes of
initial antidepressant drug choice in a Breal world^ randomized trial.
Arch Fam Med 8(4):319–325. doi:10.1001/archfami.8.4.319
35. Rojo JE, Ros S, Aguera L, de la Gandara J, de Pedro JM (2005)
Combined antidepressants: clinical experience. Acta Psychiatr
Scand Suppl 12(428):25–31
36. Andersen UA, Andersen M, Rosholm JU, Gram LF (2001)
Psychopharmacological treatment and psychiatric morbidity in
390 cases of suicide with special focus on affective disorders.
Acta Psychiatr Scand 104(6):458–465
37. Gardarsdottir H, Heerdink ER, van Dijk L, Egberts ACG (2007)
Indications for antidepressant drug prescribing in general practice in
the Netherlands. J Affect Disord 98(1–2):109–115. doi:10.1016/j.
jad.2006.07.003
Eur J Clin Pharmacol
